Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regdanvimab and CT P63 antibody cocktail - Celltrion

Next Previous
Drug Profile

Regdanvimab and CT P63 antibody cocktail - Celltrion

Alternative Names: CT-P59 and CT-P63 neutralising antibody cocktail - Celltrion; CT-P63 and CT-P59 antibody cocktail - Celltrion; CT-P63 plus Regkirona™; Neutralising antibody cocktail with CT-P59 - Celltrion; Neutralising antibody cocktail with regdanvimab - Celltrion

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltrion
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Poland (Inhalation)
  • 06 Feb 2022 Celltrion submits IND for a phase III trial for COVID-2019 infections
  • 06 Feb 2022 Celltrion plans a global phase III trial for COVID-2019 infections (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top